Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
DALLAS, Aug. 3 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), provided an update today on its clinical development strategy for ProLindac , a novel DACH platinum drug that has shown to be active in many solid tumors in human cli...
Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
LEXINGTON, Massachusetts, August 3 /PRNewswire-FirstCall/ -- Shire plc
(LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company,
today reported positive results from the first of three Phase III studies of
velaglucerase alfa, its enzyme replacement therapy in development fo...
Cyberonics Provides Update on Depression Post-Approval Study
HOUSTON, July 24 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX ) today announced that the U.S. Food and Drug Administration ("FDA") has approved the company's proposal to amend the protocol of its D-21 post-approval dosing study in depression patients treated with ...
Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
DEERFIELD, Ill., July 22, and OSAKA, Japan, July 23 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification from the U.S. Food and Drug ...
Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
BOSTON and EDISON, N.J., July 15 /PRNewswire/ -- A sub-analysis of a Phase IIb multinational study(1) with edoxaban(2) - an investigational oral Factor Xa inhibitor - provides
insights into why patients with non-valvular atrial fibrillation (AF) receiving edoxaban once daily (QD) experie...
Alfacell Provides Shareholder Update
SOMERSET, N.J., June 19 /PRNewswire-FirstCall/ --
I am grateful to have this opportunity to share with you important developments taking place at this critical juncture in our company history. This communication shall mark what I hope will be the first of many as your...
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
FRAZER, Pa., June 19 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH ) today announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show th...
Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
Phase 1 Data Demonstrate Safety and Evidence of Biological Activity in 9 of 12 Patients;
Phase 2 Study Currently Enrolling in 17 Leading U.S. Medical Centers
SAN DIEGO, May 28 /PRNewswire/ -- Celladon Corporation presented today Phase 1 data from the Calcium Up-Regulation by Percutaneou...
Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
WAYNE, Pa., May 18 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO ), a full service multinational contract research organization (CRO) that provides
design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmace...
RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
- Significant peak urine flow (Qmax) improvements within 2-6 hours of the first dose, according to published data -
CORONA, Calif., May 8 /PRNewswire-FirstCall/ -- RAPAFLO (TM) (silodosin), a new, uniquely selective alpha blocker for the treatment of the signs and symptoms of BPH, produ...
BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced that, based on discussions with the U.S. Department of Health and Human Services/Biomedical Advanced Research and Development Authority (HHS-BARDA), it is preparing a portion of its i...
Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
- Conference Call Today at 5:00 p.m. Eastern Time -
SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today reported financial results for the first quarter ended March 31, 2009, and ...
USAID Provides $5M in Emergency Support as Swine Flu Spreads
WASHINGTON, April 28 /PRNewswire-USNewswire/ -- As concerns over the spread of swine flu grow, the U.S. Agency for International Development (USAID) announced today that it is providing an additional $5 million to the World Health Organization (WHO) and the Pan American Health Organization (PAHO) ...
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
Conference Call and Webcast at 11:00 a.m. Eastern Time
THE WOODLANDS, Texas, April 28 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its...
Strativa Pharmaceuticals Provides Product Pipeline Update
Files NDA for Ondansetron Orally Dissolving Film Strip
BioAlliance to Resubmit Loramyc(R) NDA
WOODCLIFF LAKE, N.J., April 9 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: P...
Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
- Conference Call Today at 5:00 p.m. Eastern Time -
SOUTH SAN FRANCISCO, Calif., March 16 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today reported financial results for the fourth quarter and year ended Decembe...
VirtualScopics' Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
Pioneering study uses quantitative imaging endpoints from MRI analyses
ROCHESTER, N.Y., March 12 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP ), a leading provider of quantitative imaging for clinical trials, today announced that BioSyntech Inc., a Canadian medical device co...
Savient Provides Update on Pegloticase BLA
Company Files Amendments to Strengthen and Clarify BLA Data
FDA Extends PDUFA Action Date to July 30, 2009
Company to Host Conference Call
EAST BRUNSWICK, N.J., Feb. 12 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced that the Company f...
USAID Provides Malaria Assistance to Zimbabwe
WASHINGTON, Feb. 6 /PRNewswire-USNewswire/ -- The U.S. Agency for International Development (USAID) continues to provide assistance to the people of Zimbabwe, who are in the midst of an expanding humanitarian crisis. An ailing economy, food shortages and the cholera epidemic have left th...
Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
MONTVALE, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) today announced that, following a review of its clinical development portfolio and its current financial status, the Board of Directors and management have determined that it is in the best int...
Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
SEATTLE, Jan. 27 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI)
(Nasdaq and MTA: CTIC) announced today that after communication with the Food
and Drug Administration (FDA), CTI expects to begin submission of a rolling
New Drug Application (NDA) and request priority review for pixantrone to ...
American Dairy Provides Business Update
- Company Named One of China's Most Influential Companies -
- Announces Repurchase of Additional $3.77 Million of Convertible Notes -
BEIJING, Jan. 20 /PRNewswire-FirstCall/ -- American Dairy, Inc. (NYSE Arca: ADY), one of the leading producers and distributors of premium infant formula,...
Alfacell Provides ONCONASE(R) NDA Submission Update
SOMERSET, N.J., Dec. 5 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL ) today reported that the U.S. Food and Drug Administration (FDA) has scheduled a pre-NDA meeting date at the end of January 2009 for discussion of the company's planned submission of the final components of the ...
Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives
NEW YORK, Dec. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.
(Nasdaq: SGMO ) announced that the company will provide an update on milestones
achieved in 2008 and preview objectives for 2009 during its annual Investor
and Analyst Briefing to be held in New York City today.
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Company reaffirms its innovation leadership and long-term commitment to hepatitis research
KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhi...
Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals,
Inc. (Nasdaq: CADX ), a biopharmaceutical company focused on in-licensing,
developing and commercializing proprietary product candidates principally
for use in the hospital setting, today reported financial results for the
Raptor Pharmaceuticals Provides Update on Targeting Platforms
Enters Collaboration on Receptor Associated Protein (RAP)
Supports NeuroTrans(TM) Platform with Japanese Patent
NOVATO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals
Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today
announced updates on its preclinical p...
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
- Higher Sustained Virological Response Rates Recognized as Marker of
Treatment Success -
SAN FRANCISCO, Calif., Nov. 1 /PRNewswire/ -- A new,
independently-conducted study being presented at the 59th Annual Meeting of
the American Association for the Study of Liver Diseases (AASLD) shows th...
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
CIMZIA(R) Data Shows Long-term Improvements in Productivity, Quality of Life and Lessened Fatigue According to Studies Presented at American College of Rheumatology (ACR) Annual Scientific Meeting
SAN FRANCISCO, Oct. 27 /PRNewswire/ -- 5:00 AM PST -- UCB announced
today results from se...
Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
Data Analysis of Up to Four Years of Treatment Presented at ICAAC/IDSA
2008 Annual Meeting
WASHINGTON, Oct. 26 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP ) today reported a data analysis showing that
vicriviroc, its investigational CCR5 receptor antagonist, demonstrate...
Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project
Expansion of Genomic DNA from Multiple Cancer Populations Facilitates Disease Studies
ANN ARBOR, Mich., Oct. 13 /PRNewswire/ -- Rubicon Genomics, Inc. today
announced an agreement with SAIC-Frederick to amplify DNA samples for The
Cancer Atlas Genome Project.
CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients
Several abstracts highlighting CIMZIA's long-term benefits and value in
moderate to severe Crohn's disease patients presented at American College
of Gastroenterology (ACG)
ORLANDO, Fla. Oct. 7 /PRNewswire-FirstCall/ -- Data from two studies
presented this week by UCB at the American College ...
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
IRVINE, Calif., Sept. 26 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.
(Nasdaq: IDMI ) today announced that it met with representatives of the
Committee for Medicinal Products for Human Use (CHMP) and Secretariat of
the European Medicines Agency (EMEA) on September 25th, following the
Fralex provides update on timing of interim analysis results
TORONTO, Sept. 25 /PRNewswire-FirstCall/ - Fralex Therapeutics Inc.
(TSX:FXI) ("Fralex" or the "Company"), a medical technology company
developing a non-invasive neuromodulation device, today provided an update
on receiving results of the interim analysis for the RELIEF pivotal study.
Vanda Pharmaceuticals Provides Update on Iloperidone
ROCKVILLE, Md., Sept. 11 /PRNewswire-FirstCall/ -- Vanda
Pharmaceuticals Inc. (Nasdaq: VNDA ), a biopharmaceutical company focused on
the development and commercialization of clinical-stage product candidates
for central nervous system disorders, reported today that it met with the
FDA on Sep...
Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus
Proves promising for individuals living with West Nile Virus and populations susceptible such as the elderly or immune compromised
PURCHASE, N.Y., Sept. 9 /PRNewswire/ -- A recently completed study from
researchers at Colorado State University supported by the Division of
Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
Clinical Data Presented at American Academy of Dermatology Summer Meeting
PRINCETON, N.J., July 31 /PRNewswire/ -- NeoStrata today announced
findings from an ongoing 12-week study that demonstrates benefits of a
novel topically applied LCD (coal tar) solution (Psorent(TM)) versus
New Research Provides Evidence that Tea May Improve Attention and Focus, Keep Brain Cells Healthy, & Influence Genetics in Cancer
Findings Published in August Issue of Journal of Nutrition
NEW YORK, July 18 /PRNewswire/ -- Drinking four to five cups of tea a
day may help maintain a healthy mind and body, according to new research
published in a supplement to the August issue of the Journal of Nutrition.
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Submission of Five-Day Dosing Regimen sNDA Targeted for Fiscal Year-end 2008
WOODCLIFF LAKE, N.J., July 1, 2008 /PRNewswire/ -- Eisai Corporation of
North America today announced the preliminary efficacy data from a trial
initiated in 2002 comparing Dacogen(R) ...
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
- Company continues to anticipate CHMP opinion in the third quarter;
L-MTP-PE on track for final European Commission decision in the fourth quarter
IRVINE, Calif., July 1 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.
(Nasdaq: IDMI ) today announced that the CH...